REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER 2022 2021 Reported Operational (1) Currency CONSUMER HEALTH SEGMENT (2,3) OTC (5) US 670 $ 599 11.8% 11.8% - Intl 791 673 17.5% 21.7% -4.2% WW 1,461 1,273 14.8% 17.1% -2.3% SKIN HEALTH / BEAUTY US 544 634 -14.2% -14.2% - Intl 468 529 -11.6% -7.1% -4.5% WW 1,012 1,163 -13.0% -11.0% -2.0% ORAL CARE US 143 163 -12.6% -12.6% - Intl 223 254 -12.0% -8.6% -3.4% WW 366 417 -12.2% -10.2% -2.0% BABY CARE US 85 96 -11.5% -11.5% - Intl 270 293 -7.7% -4.8% -2.9% WW 355 389 -8.6% -6.4% -2.2% WOMEN'S HEALTH US 3 3 7.2% 7.2% - Intl 224 219 2.5% 8.3% -5.8% WW 228 222 2.6% 8.3% -5.7% WOUND CARE / OTHER US 112 115 -3.3% -3.3% - Intl 52 61 -15.3% -14.5% -0.8% WW 164 177 -7.4% -7.2% -0.2% TOTAL CONSUMER HEALTH US 1,557 1,611 -3.4% -3.4% - Intl 2,029 2,030 0.0% 4.1% -4.1% WW 3,586 $ 3,641 -1.5% 0.8% -2.3% See footnotes at end of schedule % Change -- 1 of 7 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER PHARMACEUTICAL SEGMENT (2,3) 2022 2021 Reported Operational (1) Currency IMMUNOLOGY US 2,501 $ 2,413 3.7% 3.7% - Intl 1,617 1,501 7.7% 13.7% -6.0% WW 4,119 3,914 5.2% 7.5% -2.3% REMICADE US 358 489 -26.8% -26.8% - US Exports (4) 80 57 40.5% 40.5% - Intl 225 232 -2.6% -1.0% -1.6% WW 663 777 -14.7% -14.2% -0.5% SIMPONI / SIMPONI ARIA US 287 255 12.5% 12.5% - Intl 283 307 -7.6% -1.9% -5.7% WW 571 562 1.5% 4.7% -3.2% STELARA US 1,379 1,331 3.6% 3.6% - Intl 909 817 11.2% 17.8% -6.6% WW 2,288 2,148 6.5% 9.0% -2.5% TREMFYA US 391 274 42.7% 42.7% - Intl 199 143 38.8% 47.9% -9.1% WW 590 418 41.3% 44.5% -3.2% OTHER IMMUNOLOGY US 6 7 -3.2% -3.2% - Intl 0 2 * * * WW 6 8 -22.0% -22.0% - INFECTIOUS DISEASES (5) US 461 512 -10.0% -10.0% - Intl 836 485 72.3% 78.6% -6.3% WW 1,297 998 30.0% 33.1% -3.1% COVID-19 VACCINE US 75 100 -24.9% -24.9% - Intl 382 0 * * * WW 457 100 * * * EDURANT / rilpivirine US 9 10 -12.6% -12.6% - Intl 239 233 2.5% 10.5% -8.0% WW 248 243 1.8% 9.6% -7.8% PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US 369 380 -3.1% -3.1% - Intl 132 166 -20.3% -15.9% -4.4% WW 501 546 -8.3% -6.9% -1.4% OTHER INFECTIOUS DISEASES US 8 21 -62.5% -62.5% - Intl 83 87 -3.8% 1.6% -5.4% WW 91 108 -15.3% -11.0% -4.3% % Change -- 2 of 7 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER 2022 2021 Reported Operational (1) Currency NEUROSCIENCE (5) US 843 771 9.3% 9.3% - Intl 898 943 -4.8% 1.5% -6.3% WW 1,741 1,715 1.5% 5.0% -3.5% CONCERTA / Methylphenidate US 35 47 -26.5% -26.5% - Intl 122 123 -1.3% 3.5% -4.8% WW 157 171 -8.3% -4.8% -3.5% INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA US 661 589 12.2% 12.2% - Intl 387 376 3.0% 9.9% -6.9% WW 1,048 965 8.6% 11.3% -2.7% RISPERDAL CONSTA US 63 67 -6.4% -6.4% - Intl 66 89 -26.1% -19.6% -6.5% WW 129 157 -17.6% -13.9% -3.7% OTHER NEUROSCIENCE US 84 67 25.5% 25.5% - Intl 323 355 -8.9% -2.8% -6.1% WW 408 422 -3.5% 1.7% -5.2% ONCOLOGY US 1,582 1,377 14.9% 14.9% - Intl 2,369 2,193 8.0% 15.0% -7.0% WW 3,950 3,570 10.6% 14.9% -4.3% DARZALEX US 953 691 37.9% 37.9% - Intl 903 674 34.0% 42.7% -8.7% WW 1,856 1,365 36.0% 40.3% -4.3% ERLEADA US 206 171 20.3% 20.3% - Intl 194 90 * * * WW 400 261 53.0% 57.5% -4.5% IMBRUVICA US 370 444 -16.7% -16.7% - Intl 668 680 -1.8% 4.5% -6.3% WW 1,038 1,125 -7.7% -3.9% -3.8% ZYTIGA / abiraterone acetate US 19 50 -62.1% -62.1% - Intl 520 588 -11.6% -5.7% -5.9% WW 539 638 -15.6% -10.1% -5.5% OTHER ONCOLOGY US 34 21 63.1% 63.1% - Intl 84 161 -47.7% -44.6% -3.1% WW 118 182 -35.1% -32.3% -2.8% % Change -- 3 of 7 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER 2022 2021 Reported Operational (1) Currency PULMONARY HYPERTENSION US 572 573 -0.2% -0.2% - Intl 279 288 -2.9% 4.0% -6.9% WW 852 861 -1.1% 1.2% -2.3% OPSUMIT US 273 272 0.5% 0.5% - Intl 170 179 -4.8% 2.0% -6.8% WW 443 450 -1.6% 1.1% -2.7% UPTRAVI US 269 259 3.9% 3.9% - Intl 56 46 20.9% 28.8% -7.9% WW 325 305 6.5% 7.7% -1.2% OTHER PULMONARY HYPERTENSION US 30 42 -29.0% -29.0% - Intl 53 63 -15.2% -8.4% -6.8% WW 83 105 -20.8% -16.8% -4.0% CARDIOVASCULAR / METABOLISM / OTHER (5) US 672 799 -15.8% -15.8% - Intl 238 245 -3.0% 0.9% -3.9% WW 910 1,044 -12.8% -11.9% -0.9% XARELTO US 508 589 -13.8% -13.8% - Intl - - - - - WW 508 589 -13.8% -13.8% - INVOKANA / INVOKAMET US 60 87 -30.7% -30.7% - Intl 68 63 7.5% 11.1% -3.6% WW 128 150 -14.6% -13.1% -1.5% OTHER US 104 122 -14.9% -14.9% - Intl 170 182 -6.6% -2.6% -4.0% WW 274 305 -10.0% -7.5% -2.5% TOTAL PHARMACEUTICAL US 6,632 6,446 2.9% 2.9% - Intl 6,237 5,655 10.3% 16.7% -6.4% WW 12,869 $ 12,101 6.3% 9.3% -3.0% See footnotes at end of schedule % Change -- 4 of 7 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER MEDTECH SEGMENT (2,3,6) 2022 2021 Reported Operational (1) Currency INTERVENTIONAL SOLUTIONS US 494 $ 434 13.8% 13.8% - Intl 597 514 16.2% 20.4% -4.2% WW 1,092 949 15.1% 17.4% -2.3% ORTHOPAEDICS US 1,289 1,249 3.2% 3.2% - Intl 899 864 4.1% 9.1% -5.0% WW 2,188 2,113 3.5% 5.6% -2.1% HIPS US 225 209 7.3% 7.3% - Intl 164 146 12.2% 17.0% -4.8% WW 389 356 9.3% 11.3% -2.0% KNEES US 201 185 8.6% 8.6% - Intl 138 132 4.1% 9.1% -5.0% WW 339 317 6.7% 8.8% -2.1% TRAUMA US 475 450 5.5% 5.5% - Intl 273 282 -3.3% 2.2% -5.5% WW 748 733 2.1% 4.2% -2.1% SPINE, SPORTS & OTHER US 387 404 -4.1% -4.1% - Intl 324 303 7.0% 11.7% -4.7% WW 712 707 0.6% 2.7% -2.1% % Change -- 5 of 7 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER 2022 2021 Reported Operational (1) Currency SURGERY US 921 898 2.5% 2.5% - Intl 1,513 1,474 2.7% 6.6% -3.9% WW 2,434 2,372 2.6% 5.0% -2.4% ADVANCED US 417 405 3.0% 3.0% - Intl 729 713 2.2% 5.4% -3.2% WW 1,146 1,118 2.5% 4.5% -2.0% GENERAL US 504 493 2.1% 2.1% - Intl 784 761 3.1% 7.7% -4.6% WW 1,288 1,254 2.7% 5.5% -2.8% VISION US 521 472 10.4% 10.4% - Intl 736 673 9.4% 16.4% -7.0% WW 1,257 1,145 9.8% 13.9% -4.1% CONTACT LENSES / OTHER US 400 371 7.7% 7.7% - Intl 511 486 5.1% 12.9% -7.8% WW 910 857 6.2% 10.6% -4.4% SURGICAL US 121 101 20.2% 20.2% - Intl 226 187 20.5% 25.7% -5.2% WW 347 288 20.4% 23.8% -3.4% TOTAL MEDTECH US 3,225 3,054 5.6% 5.6% - Intl 3,746 3,525 6.3% 11.1% -4.8% WW 6,971 $ 6,579 5.9% 8.5% -2.6% * Percentage greater than 100% or not meaningful (1) Operational growth excludes the effect of translational currency (2) Unaudited (3) Certain prior year amounts have been reclassified to conform to current year product disclosures (4) Reported as U.S. sales (6) Previously referred to as Medical Devices Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. (5) Refer to supplemental sales information schedule % Change -- 6 of 7 -- Full Year Q1 Q2 Q3 Q4 Full Year CONSUMER HEALTH SEGMENT (1) OTC (2) US 2,460 599 675 686 633 2,594 Intl 2,761 673 752 798 811 3,034 WW 5,221 1,273 1,426 1,484 1,444 5,627 PHARMACEUTICAL SEGMENT (1) INFECTIOUS DISEASES (2) OTHER INFECTIOUS DISEASES US 104 21 16 18 11 66 Intl 292 87 71 82 57 297 WW 396 108 88 99 68 363 NEUROSCIENCE (2) OTHER NEUROSCIENCE US 298 67 91 81 99 338 Intl 1,312 355 373 298 342 1,368 WW 1,610 422 464 379 441 1,706 CARDIOVASCULAR / METABOLISM / OTHER (2,3) OTHER US 600 122 116 98 110 446 Intl 794 182 178 173 140 673 WW 1,394 305 293 271 250 1,119 Note: Columns and rows within tables may not add due to rounding (1) Unaudited (3) Other is inclusive of PROCRIT / EPREX, which was previously disclosed separately (2) Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes in their respective regions Supplemental Sales Information (Dollars in Millions) Certain prior year amounts have been reclassified to conform to current year product disclosures 2020 2021 2021 -- 7 of 7 --